Total prescribing costs | £6.84 billion |
Cardiovascular drug costs | £1.74 billion |
Bendrofluazide | £21 million |
β Blockers | £89 million |
Atenolol | £21 million |
ACE inhibitors/angiotensin receptor blockers | £500 million |
Calcium channel blockers | £290 million |
Amlodipine | £140 million |